Log In
Print
BCIQ
Print
Print this Print this
 

doxepin (Silenor)

Also known as: SO-101

  Manage Alerts
Collapse Summary General Information
Company Pernix Therapeutics Holdings Inc.
DescriptionLow-dose tricyclic doxepin
Molecular Target Histamine H1 receptor (HRH1) ; Histamine receptor
Mechanism of ActionHistamine H1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInsomnia
Indication DetailsTreat insomnia; Treat insomnia characterized by nocturnal awakenings and/or early morning awakenings; Treat insomnia in elderly patients; Treat primary chronic insomnia; Treat primary sleep maintenance insomnia; Treat transient insomnia
Regulatory Designation
Partner CJ Group; Endo International plc; Procter & Gamble Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

6

$25.0M

$1.1M

$128.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today